Kiromic BioPharma (KRBP) Competitors $0.90 -0.01 (-1.10%) (As of 11/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends KRBP vs. HOTH, CYCN, BMRA, ONVO, AEZS, APVO, ORGS, HURA, ALZN, and BNOXShould you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Hoth Therapeutics (HOTH), Cyclerion Therapeutics (CYCN), Biomerica (BMRA), Organovo (ONVO), Aeterna Zentaris (AEZS), Aptevo Therapeutics (APVO), Orgenesis (ORGS), TuHURA Biosciences (HURA), Alzamend Neuro (ALZN), and Bionomics (BNOX). These companies are all part of the "pharmaceutical products" industry. Kiromic BioPharma vs. Hoth Therapeutics Cyclerion Therapeutics Biomerica Organovo Aeterna Zentaris Aptevo Therapeutics Orgenesis TuHURA Biosciences Alzamend Neuro Bionomics Hoth Therapeutics (NASDAQ:HOTH) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings. Is HOTH or KRBP more profitable? Kiromic BioPharma's return on equity of 0.00% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -89.68% -82.61% Kiromic BioPharma N/A N/A -241.14% Which has more risk and volatility, HOTH or KRBP? Hoth Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Do insiders & institutionals have more ownership in HOTH or KRBP? 7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are owned by institutional investors. 10.6% of Hoth Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Kiromic BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to HOTH or KRBP? In the previous week, Hoth Therapeutics had 2 more articles in the media than Kiromic BioPharma. MarketBeat recorded 2 mentions for Hoth Therapeutics and 0 mentions for Kiromic BioPharma. Kiromic BioPharma's average media sentiment score of 0.00 beat Hoth Therapeutics' score of -0.82 indicating that Kiromic BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Hoth Therapeutics Negative Kiromic BioPharma Neutral Which has stronger valuation and earnings, HOTH or KRBP? Hoth Therapeutics is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$7.84M-$1.32-0.63Kiromic BioPharmaN/AN/A-$20.95M-$6.55-0.14 Do analysts rate HOTH or KRBP? Hoth Therapeutics currently has a consensus price target of $3.50, suggesting a potential upside of 323.42%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Hoth Therapeutics is more favorable than Kiromic BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Kiromic BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in HOTH or KRBP? Hoth Therapeutics received 70 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 65.14% of users gave Hoth Therapeutics an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote. CompanyUnderperformOutperformHoth TherapeuticsOutperform Votes7165.14% Underperform Votes3834.86% Kiromic BioPharmaOutperform Votes150.00% Underperform Votes150.00% SummaryHoth Therapeutics beats Kiromic BioPharma on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 Media“Sleeping Giant” Crypto Set to Explode…What if I told you there's a crypto that could make Bitcoin look like small change? We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Kiromic BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRBP vs. The Competition Export to ExcelMetricKiromic BioPharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43M$2.94B$5.04B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio-0.1444.66122.4217.58Price / SalesN/A359.351,179.2973.96Price / CashN/A160.0933.5632.51Price / Book-0.123.734.694.68Net Income-$20.95M-$41.63M$118.98M$225.87M7 Day Performance-10.00%-7.92%-2.45%-2.03%1 Month Performance-25.16%-7.14%-4.03%0.07%1 Year Performance246.15%23.06%29.80%24.55% Kiromic BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRBPKiromic BioPharmaN/A$0.90-1.1%N/A+308.9%$1.43MN/A-0.1435HOTHHoth Therapeutics2.3501 of 5 stars$0.83+1.2%$3.50+323.4%-24.4%$5.70MN/A-0.654News CoverageGap UpHigh Trading VolumeCYCNCyclerion Therapeutics1.0401 of 5 stars$2.09+18.8%N/A-16.6%$5.66M$1.62M0.0030News CoverageHigh Trading VolumeBMRABiomericaN/A$0.32flatN/A-65.2%$5.46M$5.41M-0.8660ONVOOrganovo0.846 of 5 stars$0.35+2.9%N/A-75.5%$5.38M$110,000.00-0.3220Analyst ForecastNews CoverageAEZSAeterna ZentarisN/A$3.00-6.3%N/A-51.8%$5.38M$2.37M-0.2020Gap DownHigh Trading VolumeAPVOAptevo Therapeutics2.7467 of 5 stars$0.29+16.0%$8.00+2,658.6%-97.0%$5.37M$3.11M0.0050Gap UpHigh Trading VolumeORGSOrgenesis1.8119 of 5 stars$1.09+6.9%N/AN/A$5.23M$662,000.000.00150HURATuHURA BiosciencesN/A$3.29+8.9%$15.00+355.9%N/A$5.23MN/A0.00N/ANegative NewsALZNAlzamend Neuro1.9263 of 5 stars$1.31-6.4%$35.00+2,571.8%-91.7%$5.10MN/A0.004News CoverageBNOXBionomics2.0089 of 5 stars$0.28-6.6%$8.00+2,733.9%-84.7%$4.89M$10,000.000.00N/ANews Coverage Related Companies and Tools Related Companies HOTH Competitors CYCN Competitors BMRA Competitors ONVO Competitors AEZS Competitors APVO Competitors ORGS Competitors HURA Competitors ALZN Competitors BNOX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRBP) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored31 Billionaires Are Loading Up on This SectorWhy are 31 of the world's richest billionaires, like Warren Buffett, Jeff Bezos, the Walton family, and Bill G...InvestorPlace | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
